Mar. 21 at 9:29 PM
$OTLK dupixent is a blockbuster drug in the dermatology space, and now beyond, covering multiple indications. It took regeneron approximately 2 years (between its launch in 2017 into 2019) to log 50,000 patients treated. This was a drug that was desperately needed in the dermatology space. If Outlook receives
$500 per shot they would need 50,000 doses to hit the
$25,000,000 mark. That is their quarterly burn. Nothing I am saying here is opinion or fabricated. This can all easily be fact checked. @AnalystLLM accuses me of trying persuade retail not to buy shares. That is not my purpose. Buy as much as you like, but if you hold long be warned. Swing it, scalp it, play it how you like. Holding long is a death sentence for your money. The stock is down over 90% since the last RS. My purpose is to prevent you from making the same mistakes I have made in the past, and to provide you with verifiable information, not pie in the sky dreams.
